Skip to main content

Table 1 Study entry characteristics for groups classified by length in study

From: Changes in cognitive domains during three years in patients with Alzheimer's disease treated with donepezil

Characteristic

Study entry only

6-month completers

1-year completers

2-year completers

3-year completers

Total SATS sample

N

38

39

93

93

158

435

Sex (men)

31.6%

25.6%

32.3%

45.2%

35.4%

35.2%

Age (years)

75.8 ± 4.67

77.7 ± 4.17

74.7 ± 6.21

74.2 ± 6.87

73.8 ± 6.99

74.6 ± 6.53

Duration (yrs)

3.43 ± 2.38

2.92 ± 1.53

3.08 ± 2.04

3.13 ± 2.15

3.11 ± 2.61

3.11 ± 2.26

APOE ε4 allelea

69.7%

60.0%

74.7%

61.5%

63.9%

66.0%

MMSE

21.7 ± 4.01

20.9 ± 4.49

21.6 ± 5.18

22.0 ± 4.21

23.1 ± 4.15

22.0 ± 4.55

ADAS-Cog (70)

22.9 ± 10.7

22.7 ± 9.26

21.9 ± 11.2

21.9 ± 9.89

18.2 ± 9.03

20.7 ± 10.0

ADAS-Cog (85)

32.6 ± 12.6

32.2 ± 10.9

30.7 ± 12.8

31.3 ± 11.4

26.8 ± 10.8

30.0 ± 11.8

  1. Note. Values are presented as Mean ± SD or percent, a Percentage carrying at least one APOE ε4 allele.